East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Saxagliptin Tablets. Aurobindo Pharma’s Saxagliptin Tablets are an are an AB-rated generic equivalent to the reference listed drug (RLD),Onglyza Tablets, manufactured by AstraZeneca AB.

Saxagliptin Tablets, are indicated for :

• An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings.